GlobalData on MSN3d
Travere takes rare disease kidney drug to FDA despite failed trial
Travere’s stock price climbed by 14% following the announcement that it will seek an FDA label expansion for Filspari.
Travere Therapeutics stock rises on sNDA submission plans for FILSPARI
Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX) rose 7% following the company's announcement of its intent to submit a ...
Travere Therapeutics, Inc.: Travere Therapeutics to Submit sNDA for FILSPARI (sparsentan) in FSGS
Company completed Type C meeting with FDA, aligning on its plan to submit an sNDA; submission expected around end of 1Q25 If approved, FILSPARI could be the first and only approved medicine indicated ...
Travere Therapeutics to Submit sNDA for FILSPARI® (sparsentan) in FSGS
Company completed Type C meeting with FDA, aligning on its plan to submit an sNDA; submission expected around end of 1Q25If approved, FILSPARI ...
manilatimes4d
Optima Health Secures First License with the NHS for its Digital Assessment Routing Tool 'DART'
LONDON, UK, 11 February 2025, Optima Health (AIM: OPT), the UK's leading provider of technology enabled corporate health and ...